arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR

Anbio Biotechnology

NNNN
$10.12 ▲ +0.18 (+1.86%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
4 Visible periods
3 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bullish
auto_awesome

Analytical Summary

Anbio Biotechnology shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
67
Returns
88
Cash Quality
10

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 4 quarters